In October 2023, TAP made an equity investment in Enterome to "Support the ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymphoma."
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, allowing it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Its first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines.
EO2463 is a clinical-stage off-the-shelf OncoMimics™ peptide-based immunotherapy. It combines four microbial-derived OncoMimics™ peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes in B cell Tumor-Associated Antigens CD20, CD22, CD37, and CD268 (BAFF receptor), as well as a helper CD4 peptide, UCP2. The SIDNEY trial is a multicenter, Phase 1/2 trial investigating EO2463 in monotherapy and in combination with standard of care - rituximab and rituximab in combination with lenalidomide – for treatment of patients with indolent NHL (NCT04669171).
For more information about Enterome, visit enterome.com.
Recent News
- June 15, 2026 - presented Phase 1/2 iNHL interim data at EHA 2026 demonstrating durable-induced CD8 T cell responses and clinical activity
- May 28, 2026 - received FDA Orphan Drug Designation for EO2463 to treat “watch-and-wait” indolent non-Hodgkin lymphoma
- December 9, 2025 - presented interim Phase 2 results for EO2463 to treat follicular lymphoma at ASH 2025
- October 16, 2025 - received FDA Fast Track designation in follicular lymphoma for EO2463
- June 12, 2025 - raised $19 million to fund clinical development of immunotherapy to treat follicular lymphoma, including TAP participation
- December 10, 2024 - EO2463 shows early response in newly diagnosed follicular lymphoma as a potential alternative to ‘Watchful Waiting’
- October 30, 2023 - announced receiving a €3 million investment from the Therapy Acceleration Program® (TAP). The funding will propel the ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymphoma